Action Point Financial Planning’s Krystal Biotech KRYS Stock Holding History

Action Point Financial Planning’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.23K	Buy	+6	New	+$1.79K	﹤0.01%	2208

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Action Point Financial Planning's KRYS Position: Q2 2026 in Review

Action Point Financial Planning opened a new position in Krystal Biotech (KRYS) in Q2 2026: 6 shares worth $2.23K. The stake represents ﹤0.01% of the portfolio and ranks #2208 among its holdings.

419 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

Action Point Financial Planning held 6 shares of Krystal Biotech worth $2.23K as of Q2 2026.
Krystal Biotech was a new Action Point Financial Planning position in Q2 2026.
Krystal Biotech made up ﹤0.01% of Action Point Financial Planning's portfolio in Q2 2026, its #2208 holding.
419 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Action Point Financial Planning's 13F filing for Q2 2026, filed 14 Aug 2026.